Several new biomarkers at the genomic, transcriptomic, and epigenetic levels have been developed, including: (1) ADXBLADDER, a novel ELISA test for Mini-chromosome maintenance 5; (2) Cxbladder Monitor; (3) XPERT BC, measure mRNA levels of ABL1, CRH, IGF2, UPK 1B, and ANXA 10; (4) UroMark assay; and (5) AssureMDX, test of the DNA methylation of OTX1, ONECUT2, and TWIST1 and somatic statuses of FGFR3, TERT, and HRAS in urine (Dangle et al., 2009; Tabayoyong and Kamat, 2018). This evidence concerns the gene IGF2 and breast cancer.